Objective Explored the efficacy， safety and prognostic factors of furoquinitinib alone and in combination with PD-1 monoclonal antibody in advanced metastatic colorectal cancer that failed to be treated with standard regimens. Methods From June 2018 to December 2021，31 patients who were treated with Furoquintinib combined with PD-1 inhibitor，42 patients who were treated with Furoquintinib alone and 35 patients who were treated with fourth-line chemotherapy were included as the research objects. The efficacy，survival time and major adverse reactions of patients were analyzed retrospectively，and the risk factors of progression-free survival （PFS） and overall survival （OS） were discussed. Results Significant differences in PFS were observed in the PD-1 inhibitor combined with furoquinitinib group compared with the chemotherapy group or the monotherapy group， and significant differences in OS compared with the chemotherapy group. The degree of differentiation and treatment regimen were independent risk factors affecting PFS in patients in the furoquinitinib combining PD-1 inhibitor versus chemotherapy group， while the treatment regimen was an independent risk factor affecting patients' OS. The degree of differentiation was an independent risk factor for PFS in patients in the PD-1 monoclonal antibody combination versus single agent group. The incidence of several adverse reactions was reduced with furoquinitinib alone or in combination with PD-1 inhibitor compared with conventional chemotherapy， while the incidence of hypertension was increased. Conclusions Furoquinitinib in combination with PD-1 monoclonal antibody has potential efficacy and a manageable safety profile in the backline treatment of patients with advanced mCRC. The degree of differentiation may be an independent risk factor for PFS in patients.